Chunghwa Chemical Synthesis & Biotech Co Ltd (1762)

Currency in TWD
27.15
-1.75(-6.06%)
Closed·
1762 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.9528.45
52 wk Range
24.2044.75
Key Statistics
Bid/Ask
27.05 / 27.30
Prev. Close
28.9
Open
28
Day's Range
26.95-28.45
52 wk Range
24.2-44.75
Volume
265.51K
Average Volume (3m)
96.3K
1-Year Change
11.2705%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1762 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
0.75 / --
Revenue / Forecast
305.18M / --
EPS Revisions
Last 90 days

1762 Income Statement

Compare 1762 to Peers and Sector

Metrics to compare
1762
Peers
Sector
Relationship
P/E Ratio
−69.2x28.6x−0.2x
PEG Ratio
−0.880.080.00
Price/Book
0.7x2.7x2.6x
Price / LTM Sales
2.1x4.3x2.6x
Upside (Analyst Target)
-22.5%76.9%
Fair Value Upside
Unlock14.4%14.9%Unlock

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the manufacturing, sale, and wholesale of western medicine in Taiwan and internationally. The company offers biotechnology products, including Anidulafungin antifungal medication, Caspofungin Acetate antifungal medication, Dalbavancin Hydrochloride Bacterial Skin Infection Drug, Everolimus, immunosuppressant and anticancer drug), Midostaurin for treating acute myeloid leukemia, Pneumocandin B0 antifungal intermediate, Rapamycin, Rezafungin acetate antifungal medication, Semaglutide weight loss medication, and Tacrolimus immunosuppressant, as well as Mycophenolate Mofetil, Mycophenolate Mofetil HCl, and Mycophenolate Sodium immunosuppressive drugs. It also provides non-biotechnology products, such as Abaloparatide osteoporosis medication, Baricitinib rheumatoid arthritis medication, Brivaracetam antiepileptic drug, Difelikefalin Acetate Pruritus, Edoxaban Tosylate Monohydrate, Eltrombopag Olamine, Eslicarbazepine Actate, Ethyl Icosapentate, Lanreotide Acetateacromegaly), Ozanimod HCl medicine for multiple sclerosis, Ribociclib for breast cancer medication, Plecanatide chronic idiopathic constipation medication, Ribociclib breast cancer medication, Selumetinib Sulfate for neurofibromatosis, Setmelanotide Acetate genetic obesity drug, Sugammadex Sodium anesthesia recovery medication, Tofacitinib Citrate rheumatoid arthritis medication, Trandolapril antihypertensive medication, Trilaciclib Dihydrochloride bone marrow protectant, Tenapanor HCl medication for constipation-predominant irritable bowel syndrome and hyperphosphatemia in dialysis patients. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. and changed its name to Chunghwa Chemical Synthesis & Biotech Co., Ltd. in January 2003. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.

Employees
198
Market
Taiwan

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
578.44K0.75%17.44M
Other Institutional Investors
24.54M31.91%739.90M
Public Companies & Retail Investors
51.80M67.34%1.56B
Total
76.92M100.00%2.32B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Cenra Inc.28.05%21,575,064650,488
Wang Ming-Ning Memorial Foundation2.20%1,691,98251,013

FAQ

What Is the CCSB (1762) Stock Price Today?

The CCSB stock price today is 27.15 TWD.

What Stock Exchange Does CCSB Trade On?

CCSB is listed and trades on the Taiwan Stock Exchange.

What Is the Stock Symbol for CCSB?

The stock symbol for CCSB is "1762."

What Is the CCSB Market Cap?

As of today, CCSB market cap is 2.09B TWD.

What Is CCSB's Earnings Per Share (TTM)?

The CCSB EPS (TTM) is -0.55.

When Is the Next CCSB Earnings Date?

CCSB will release its next earnings report on Nov 23, 2026.

From a Technical Analysis Perspective, Is 1762 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has CCSB Stock Split?

CCSB has split 0 times.

How Many Employees Does CCSB Have?

CCSB has 198 employees.

What is the current trading status of CCSB (1762)?

As of Nov 21, 2026, CCSB (1762) is trading at a price of 27.15 TWD, with a previous close of 28.90 TWD. The stock has fluctuated within a day range of 26.95 TWD to 28.45 TWD, while its 52-week range spans from 24.20 TWD to 44.75 TWD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.